Hemab Therapeutics Appoints Anant Murthy as Chief Operating Officer to Lead Global Market Access and Commercialization Efforts for Promising Pipeline Treatments.

Hemab Therapeutics has appointed Anant Murthy, PhD, as its Chief Operating Officer. Murthy brings a wealth of experience in market access and commercialization, with a proven track record of successful specialty medicine launches. He will lead the company's efforts to bring its pipeline of treatments for Glanzmann thrombasthenia, Von Willebrand disease, and other bleeding disorders to patients worldwide. Murthy's appointment is seen as a pivotal moment for the company, which is poised to make significant strides in the availability and accessibility of life-changing therapies.

Hemab Therapeutics, a clinical-stage biotechnology company focused on developing prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, has announced the appointment of Anant Murthy, PhD, as its Chief Operating Officer (COO). Murthy brings a wealth of experience in market access and commercialization, having held senior leadership roles at argenx, Alnylam Pharmaceuticals, ARIAD Pharmaceuticals, and Celgene Corporation [1].

In his new role, Murthy will oversee Hemab's global efforts in market access, launch, and commercialization. His primary focus will be on bringing Hemab's pipeline of treatments for Glanzmann thrombasthenia (GT), Von Willebrand disease (VWD), and other bleeding disorders to patients worldwide. Hemab's strategic guidance, Hemab 1-2-5™, aims to build a pipeline of development programs to deliver innovative solutions for patients with high unmet need diseases [1].

Murthy's appointment is seen as a pivotal moment for the company. His extensive experience in delivering specialized medicines to patients facing significant health challenges positions Hemab to make significant strides in the availability and accessibility of life-changing therapies. Benny Sorensen, MD, PhD, CEO of Hemab, stated, "We are thrilled to welcome Anant as our COO. His extensive experience, coupled with his creative and innovative thinking, makes him the perfect fit for Hemab to ensure our breakthrough treatments reach patients who have waited decades for preventative options" [1].

Dr. Murthy expressed his excitement about joining Hemab, stating, "I am excited to join Hemab, a company deeply committed to patients with bleeding disorders who have been underserved for decades. Hemab is a company fueled by integrity, passion, perseverance, and smart work across multiple geographic areas. I look forward to collaborating with this talented team to build the global infrastructure needed to bring our groundbreaking therapies to those who need them the most" [1].

Hemab Therapeutics is dedicated to addressing the needs of patients with rare and complex blood disorders. With Dr. Murthy at the helm of operations, the company is poised to make significant strides in the availability and accessibility of life-changing therapies.

References:
[1] https://finance.yahoo.com/news/hemab-therapeutics-expands-leadership-appointment-120000711.html